WEBULL
WebtradeDownload

Cogstate (ASX:CGS) Shares Gain Backing From Contract Surge And Margins

Simply Wall St · 1d ago

Cogstate came into this result with the stock at A$2.93 and a solid double digit return over the past three months, so expectations were already warm. The headline today is simple: this is a revenue and margin story. Full year revenue reached about US$60.9m and earnings from continuing operations were about US$11.9m, which puts the reported net margin near 19.5%. The bigger hook for you as an investor is forward visibility, with management highlighting a sharp jump in new contracts and a healthy pool of contracted future revenue.

Is Cogstate trading at a genuine discount, or does the earnings quality risk justify the lower P/E versus peers? Compare the current share price against our detailed valuation analysis for Cogstate

FY 2026 Earnings Summary

  • Revenue (FY 2026 vs FY 2025): US$60.86m vs. US$53.09m (up about 15%)
  • Net Income from Continuing Operations (FY 2026 vs FY 2025): US$11.90m vs. US$10.14m (up about 17%)
  • Basic EPS (FY 2026 vs FY 2025): US$0.0696 vs. US$0.0592 (up about 18%)
  • Net Profit Margin (FY 2026 vs FY 2025): 19.5% vs. 19.1% (slight improvement in profitability)

Prefer clear visual charts instead of a dense wall of numbers and earnings tables? View Cogstate’s full financial picture, including its valuation breakdown at a glance, in our company report for Cogstate.

ASX:CGS Trailing 12-Month Earnings & Revenue History as at Aug 2026
ASX:CGS Trailing 12-Month Earnings & Revenue History as at Aug 2026

Cogstate bull story gets real revenue proof

Bulls argue Cogstate is turning neuroscience tools and AI into a scalable, higher margin platform with better visibility. FY26 goes a long way to backing that up. Revenue of about US$60.9m and net margin near 19.5% line up with the company’s talk of operating leverage, helped by an EBIT margin in the mid 20s and H2 EBIT reportedly around 30 to 35%. The real milestone is contracts. A$89m of new contract sales in FY26, very large growth year on year, and 171 active trials with 90 new starts show that the Medidata and other channel partnerships are feeding a much broader trial base. Contracted future revenue of A$118.5m, with A$48.3m expected in FY27, gives the kind of forward visibility bulls have been looking for.

Bear case tests earnings quality and reliance risks

Bears worry Cogstate leans too hard on a few pharma trials, spends ahead of revenue on AI, and flatters earnings with one offs. Some of that caution still holds. Gross margin eased from 61% to 58% as capacity spending pulled on profitability, even though H2 recovered to about 62%. Management also flagged that FX hedging helped FY26 EBITDA and should not be viewed as repeatable, which supports concerns about earnings quality. The business remains closely tied to CNS clinical trial funding, and management itself highlighted timing lumpiness in contract conversion. At the same time, the sharp rise in active trials and broader indication mix into mood, sleep and rare disease slightly reduces concentration risk, so the bear argument now leans more on execution of the multi year AI platform than on immediate financial stress.

Compare whether Cogstate’s contract momentum and margin profile align with institutional expectations. See the consensus price target analysis for Cogstate.

Stay Ahead With Cogstate Insights

If Cogstate’s growing contract base and current margin profile have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a setup that suits your entry plan. Once you are invested, use the Portfolio Command Center to cut through noise and focus on concise updates that matter for your holdings. For the longer term, tap into the collective views of other investors through the Community and see how sentiment and thesis work evolve over time. This way you can spot potential catalysts or risks early and stay a step ahead of the broader market.

Seeking Alternatives Beyond Cogstate Today

Fresh stock ideas do not sit still. Breakout potential, early momentum and under the radar stories can get caught quickly. Scan these curated shortlists before the best entry points slip away and act promptly.

  • Capture potential upside from companies with strong cash generation and robust balance sheets by reviewing our curated 14 high quality undervalued stocks while they are still flying under most investors’ radars.
  • Spot early leaders supplying the picks and shovels for AI infrastructure growth by scanning the carefully filtered 56 AI infrastructure stocks before momentum traders increase their activity.
  • Consider positioning for long term demand in critical materials by checking the focused 9 top copper producer stocks while these producers are still dropping clues rather than headlines.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.